A Broken RNA Signal in Brain Cells Is Tied to Faster Alzheimer's Decline

Researchers studying 1,672 people with autopsy-confirmed Alzheimer's disease found that abnormal 'cryptic' RNA from the UNC13A gene — a molecular byproduct of TDP-43 dysfunction — tracks closely with worse memory, greater impairment and faster cognitive decline. The signature, measurable in brain tissue, could become a biomarker for disease progression and a target for therapies that go beyond amyloid and tau.

Key Takeaways

Researchers studying 1,672 people with autopsy-confirmed Alzheimer's disease found that abnormal 'cryptic' RNA from the UNC13A gene — a molecular byproduct of TDP-43 dysfunction — tracks closely with worse memory, greater impairment and faster cognitive decline.
The signature, measurable in brain tissue, could become a biomarker for disease progression and a target for therapies that go beyond amyloid and tau.

AI synthesis2 sources3

Alzheimer's disease is most often described through its two famous hallmarks: sticky amyloid-beta plaques and twisted tau tangles. But a growing number of patients also carry a third pathology — dysfunction of a protein called TDP-43, long known for its role in ALS and frontotemporal dementia. New research from the University of Miami Miller School of Medicine suggests that when TDP-43 goes wrong, it may help explain why some Alzheimer's patients decline far faster than others.

The team, led by biochemist Mercedes Prudencio, focused on a gene called UNC13A, which is essential for nerve cells to release neurotransmitters at synapses. In ALS and FTD, TDP-43 dysfunction is known to disrupt how UNC13A's RNA is processed, producing abnormal 'cryptic' RNA molecules. The researchers wanted to know whether the same mechanism influences Alzheimer's disease.

To find out, they analyzed genetic, clinical and neuropathological data from 1,672 people with autopsy-confirmed Alzheimer's disease, hundreds of whom also showed TDP-43 pathology. They additionally examined data from more than 466,000 UK Biobank participants. A common genetic variant of UNC13A was associated with worse cognitive performance and greater functional impairment, and carrying two copies of the risk variant was linked to a higher likelihood of dementia in the broader population.

The most striking finding, however, came from brain tissue itself. Higher levels of abnormal UNC13A RNA were strongly associated with poorer cognition, greater impairment and faster cognitive decline over time — across multiple clinical measures, and more informative than genetic status alone. The same relationship did not appear in another gene affected by TDP-43 dysfunction, suggesting UNC13A plays a uniquely important role in Alzheimer's progression.

"We know that people with AD who also have TDP-43 dysfunction often experience a faster and more severe decline," Prudencio said. But TDP-43 pathology can currently only be detected at autopsy, and today's treatments mainly target amyloid and tau. The new findings suggest that measuring UNC13A cryptic RNA could offer a window into ongoing biological changes in the living brain — a potential biomarker for who is at greatest risk of rapid decline.

There is also a therapeutic angle: earlier experimental work has shown that correcting UNC13A missplicing can restore neuronal function in laboratory models. If those results hold, therapies aimed at TDP-43 or its downstream effects could one day slow cognitive decline in the large subgroup of Alzheimer's patients whose disease involves this pathway, moving toward more personalized treatment.